CAROLINA CANCER NANOTECHNOLOGY TRAINING PROGRAM (C-CNTP)

卡罗莱纳州癌症纳米技术培训计划 (C-CNTP)

• 批准号: 10650745
• 负责人: ALEXANDER V KABANOV
• 金额: $ 38.86万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-07-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10650745
• 关键词: Malignant Neoplasms; Nanotechnology; Training Programs

This proposal seeks competing continuation of the NIH T32 Carolina Cancer Nanotechnology Training Program (C-CNTP). The program started in 2015 with the support of the NIH Ruth L. Kirschstein National Research Service Award. The goal of the program is to make a major contribution to the growth of the cancer nanotechnology workforce by providing training and research experience to a highly select cohort of postdoctoral fellows. During four years since its initiation the program has recruited 15 excellent fellows of whom 5 have completed training and moved into tenure track assistant professors, industry and FDA positions, 8 continue training with the NIH T32 support and 2 are in the final stages of training with other support sources in the labs of their mentors. We have assembled a team of 20 outstanding Program faculty from 11 departments and 3 schools at the University of North Carolina Chapel Hill with specific expertise in physical and material sciences, chemistry, pharmacoengineering, drug delivery, computational modeling as well as basic biomedical research and clinical science, all of whom have demonstrated strong interests, capabilities and collaborations at the interface between nanoscience and cancer. The objectives of the C-CNTP are to: 1) recruit an elite group of talented postdoctoral fellows from diverse backgrounds with PhD, MD or PharmD and provide them with outstanding postdoctoral experience including focused didactic training and co-mentored research experience with faculty mentors from complementary fields; 2) provide each trainee with intensive introductory training with online video library of recorded lectures followed by workshops and didactic courses to remediate differences in their backgrounds and to deepen the knowledge and understanding in the key areas of cancer nanotechnology; and 3) facilitate transition of trainees to independence by providing them with opportunities to a) conduct original cancer nanotechnology research projects; b) apply for the individual cancer nanotechnology Pilot Grants within C-CNTP, and c) acquire written and oral communications skills needed to publish manuscripts, report results, and write successful individual extramural support applications focused on problems of cancer nanotechnology. We are committed to developing a world-class postdoctoral training program that capitalizes on the existing strengths in cancer nanotechnology research, consolidates diverse research and education resources across several academic units, and becomes a significant contributor to addressing the Nation's research needs in cancer nanotechnology.

本提案寻求NIH T32卡罗来纳州癌症纳米技术培训计划的竞争性延续

项目成果

Preparation of an Orthotopic, Syngeneic Model of Lung Adenocarcinoma and the Testing of the Antitumor Efficacy of Poly(2-oxazoline) Formulation of Chemo-and Immunotherapeutic Agents.

肺腺癌原位同基因模型的制备以及化疗和免疫治疗剂聚（2-恶唑啉）制剂的抗肿瘤功效测试。

• DOI: 10.21769/bioprotoc.3953
• 发表时间: 2021
• 期刊: Bio-protocol
• 影响因子: 0.8
• 作者: Vinod,Natasha;Hwang,Duhyeong;Azam,SalmaH;VanSwearingen,AmandaED;Wayne,Elizabeth;Fussell,SloaneChristian;Sokolsky-Papkov,Marina;Pecot,ChadV;Kabanov,AlexanderV
• 通讯作者: Kabanov,AlexanderV

Targeting Accessories to the Crime: Nanoparticle Nucleic Acid Delivery to the Tumor Microenvironment.

• DOI: 10.3389/fphar.2018.00307
• 发表时间: 2018
• 期刊: Frontiers in pharmacology
• 影响因子: 5.6
• 作者: Harrison EB;Azam SH;Pecot CV
• 通讯作者: Pecot CV

Influenza Virus and SARS-CoV-2 Vaccines.

• DOI: 10.4049/jimmunol.2001287
• 发表时间: 2021-06-01
• 期刊: Journal of immunology (Baltimore, Md. : 1950)
• 作者: Sandor AM;Sturdivant MS;Ting JPY
• 通讯作者: Ting JPY

A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse.

• DOI: 10.1016/j.jconrel.2018.06.002
• 发表时间: 2018-08-28
• 期刊: Journal of controlled release : official journal of the Controlled Release Society
• 作者: McSweeney MD;Wessler T;Price LSL;Ciociola EC;Herity LB;Piscitelli JA;Zamboni WC;Forest MG;Cao Y;Lai SK
• 通讯作者: Lai SK

Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma.

纤维蛋白凝胶增强胶质母细胞瘤中嵌合抗原受体 T 细胞的抗肿瘤作用。

• DOI: 10.1126/sciadv.abg5841
• 发表时间: 2021-10-08
• 期刊: Science advances
• 影响因子: 13.6
• 作者: Ogunnaike EA;Valdivia A;Yazdimamaghani M;Leon E;Nandi S;Hudson H;Du H;Khagi S;Gu Z;Savoldo B;Ligler FS;Hingtgen S;Dotti G
• 通讯作者: Dotti G